Immune-Mediated Therapies in Lymphoma

被引：1

作者：

Forbes, Sheryl G. ^{[1
]}

Mistry, Haleigh E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA

来源：

SEMINARS IN ONCOLOGY NURSING | 2019年 / 35卷 / 05期

关键词：

Non-Hodgkin lymphoma; Hodgkin lymphoma; Immune-mediated therapy; Monoclonal antibody; Checkpoint inhibitors; PI3 kinase inhibitors; Immune modulators; Bruton's tyrosine kinase inhibitors; BCL-2; inhibitors; CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; HODGKIN; MANAGEMENT; NIVOLUMAB; MULTICOHORT; VENETOCLAX; FAILURE;

D O I：

10.1016/j.soncn.2019.08.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To review types of lymphoma, risk factors, and evaluate novel immune-mediated therapies, including side effects and management of immune-mediated toxicities. Data Source: Published literature, national statistics, and Web sites. Conclusion: Novel biologic agents are being developed with the potential to improve outcomes. However, these novel agents pose unique and sometimes serious adverse events. Implications for Nursing Practice: The immune-mediated adverse events require a multidisciplinary approach and early identification. It is imperative providers and nurses are educated on the management of the unique toxicities caused by lymphoma treatment. (C) 2019 Elsevier Inc. All rights reserved.

引用

页数：6

共 22 条

[1] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[2] Non-Hodgkin lymphoma [J].

Armitage, James O. ;

Gascoyne, Randy D. ;

Lunning, Matthew A. ;

Cavalli, Franco .

LANCET, 2017, 390 (10091) :298-310

[3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[4] Novel CD20 monoclonal antibodies for lymphoma therapy [J].

Cang, Shundong ;

Mukhi, Nikhil ;

Wang, Kemeng ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5

[5] Novel agents for relapsed and refractory follicular lymphoma [J].

Cheah, Chan Yoon ;

Fowler, Nathan H. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (01) :41-48

[6] Idelalisib in the management of lymphoma [J].

Cheah, Chan Yoon ;

Fowler, Nathan H. .

BLOOD, 2016, 128 (03) :331-336

[7] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Fanale, Michelle A. ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Zhang, Yinghua ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2125-+

[8]

Colevas AD, 2004, J CLIN ONCOL, V22, p543S

[9]

Columbus G, 2019, FDA GRANTS UMBRALISI

[10] Venetoclax: First Global Approval [J].

Deeks, Emma D. .

DRUGS, 2016, 76 (09) :979-987

← 1 2 3 →